Aquestive (NASDAQ: AQST) CFO shares withheld for PSU taxes

Rhea-AI Filing Summary

Aquestive Therapeutics, Inc. Chief Financial Officer Ernest A. Toth Jr. reported a routine tax-related share disposition. On May 5, 2026, 92,652 shares of common stock were withheld at $4.18 per share to cover taxes on vesting Performance Stock Units. After this withholding, he continues to directly hold 283,460 shares of Aquestive common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider TOTH A ERNEST JR

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	92,652	$4.18	$387K

Holdings After Transaction: Common Stock — 283,460 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 92,652 shares Withholding price: $4.18 per share Shares held after transaction: 283,460 shares

3 metrics

Shares withheld for taxes 92,652 shares Common stock withheld at $4.18 per share for PSU tax withholding

Withholding price $4.18 per share Value used for 92,652 withheld common shares

Shares held after transaction 283,460 shares Direct common stock holdings following tax-withholding disposition

Key Terms

Performance Stock Units, tax withholding obligation, Form 4

3 terms

Performance Stock Units financial

"in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

tax withholding obligation financial

"shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation"

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TOTH A ERNEST JR

(Last) (First) (Middle)

C/O AQUESTIVE THERAPEUTICS, INC.

30 TECHNOLOGY DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		F		92,652(1)	D	$4.18	283,460	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligation in connection with the vesting of certain Performance Stock Units ("PSUs") previously granted to the Reporting Person.

Remarks:

	/s/ Thomas Zalewski, as Attorney-In-Fact	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Aquestive Therapeutics (AQST) disclose in this Form 4?

Aquestive Therapeutics reported its Chief Financial Officer had shares withheld to cover taxes. The filing shows 92,652 common shares were withheld at $4.18 per share upon vesting of previously granted Performance Stock Units, a routine compensation-related event rather than an open-market stock sale.

How many AQST shares were withheld for the CFO’s tax obligations?

The filing states that 92,652 shares of Aquestive Therapeutics common stock were withheld. These shares were retained by the company to satisfy the CFO’s tax withholding obligation tied to the vesting of certain Performance Stock Units previously granted as part of his compensation.

At what price were the withheld AQST shares valued in this transaction?

The withheld Aquestive Therapeutics shares were valued at $4.18 per share. This value applies to the 92,652 common shares used to satisfy the Chief Financial Officer’s tax withholding obligation associated with the vesting of his Performance Stock Units.

How many AQST shares does the CFO hold after this tax withholding?

Following the tax withholding transaction, the CFO directly holds 283,460 shares of Aquestive Therapeutics common stock. This post-transaction holding reflects his remaining direct ownership after 92,652 shares were withheld to cover the tax obligations from PSU vesting.

Was this AQST insider transaction an open-market sale of shares?

No, the Form 4 describes a tax-withholding disposition, not an open-market sale. Shares were withheld by Aquestive to satisfy the CFO’s tax obligations on vesting Performance Stock Units, meaning no discretionary sale of shares into the market occurred in this transaction.